AGP Executive Report
Last update: 2 hours agoHepatitis B Trial: A watchdog group has published its field investigation into a proposed U.S.-funded study involving 14,000 newborns in Guinea-Bissau. The trial would delay the birth-dose vaccine for half the babies until six weeks of age. Investigators raised concerns about consent, ethics and conflicts of interest in local oversight. Approval Dispute: Guinea-Bissau’s health minister says the government has not authorized the study, despite approval by a Danish university ethics committee. The vaccine is recommended by the WHO within 24 hours of birth to help prevent hepatitis B infection, which can cause lifelong liver disease.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
